A Novel Platform for Antibody Discovery, Engineering and Validation
We Target Human Diseases with Antibodies
Antibody therapies are an increasingly important tool for treating diseases like cancer, immune disorders, and viral infections. The AbbraTech platform technology enables the discovery of antibodies against disease targets that are not accessible with conventional approaches.
The Power of Epivolve
Enables Site-Specific Antibody Discovery
Overcomes Low Immunogenicity
Bypasses Immune Tolerance
Facilitates Structure-Guided Discovery
About Us
The company was founded in 2020 in Branford, Connecticut, by a team of experienced and successful life science industry researchers. AbbraTech’s mission is to empower discovery efforts for antibodies against drug targets that are otherwise beyond the reach of modern approaches. AbbraTech’s EPIVOLVEsm technology is a generalizable platform capable of driving antibody recognition of any exposed region of a target protein, regardless of the underlying sequence. We seek to leverage the power of this platform technology to discover next-generation medicines alongside our industry and academic partners.